Pfizer well ahead of estimates on 1st-qtr results

3 May 2016

US pharma giant Pfizer (NYSE: PFE) has posted first quarter 2016 earnings per share (EPS) figures which are almost 22% ahead of analysts’ expectations.

The adjusted diluted EPS figure was $0.67, compared to estimates of $0.55, and 32% ahead of the $0.51 total for the same period last year.

Sales of new cancer treatments and the acquisition of the injectable drugmaker Hospira in September last year have contributed to Pfizer’s first quarter 2016 reported revenues of $13.01 billion, reflecting 26% operational growth compared to the first three months of 2015. Analysts polled by Thomson Reuters had forecast revenue of $12.02 billion.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK